What is Slope?
Slope operates as a specialized provider of healthcare software, engineered to mitigate inventory outages within the complex clinical trial ecosystem. The platform serves as a vital bridge between clinical research sites and their respective supply chains, ensuring seamless coordination of devices, pharmaceuticals, and diagnostic kits. By facilitating real-time traceability from suppliers to patients, Slope effectively reduces the administrative burden and logistical friction inherent in global clinical trials. Founded in 2016 and headquartered in San Francisco, the firm has established itself as a critical utility for organizations seeking to optimize trial execution through digital transformation and supply chain visibility.
How much funding has Slope raised?
Slope has raised a total of $900K across 1 funding round:
Angel/Seed
$900K
Angel/Seed (2017): $900K with participation from Undisclosed
Key Investors in Slope
Undisclosed Investors
What's next for Slope?
With this major strategic investment, Slope is poised to accelerate its enterprise-level expansion and enhance its core software capabilities. The company is expected to focus on scaling its real-time tracking infrastructure to support more complex, multi-site clinical studies. As the demand for data-driven supply chain management in life sciences continues to grow, Slope's ability to provide end-to-end visibility will likely serve as a key differentiator. Future growth will likely involve deepening integrations with global pharmaceutical suppliers and expanding its footprint in the clinical research organization market, ensuring that critical trial materials are delivered with precision and reliability.
See full Slope company page
